Policy proposals to restrict U.S. biopharmaceutical investment involving China could have major unintended consequences for American innovation and economic competitiveness. As China becomes an increasingly important source of biopharmaceutical innovation, such restrictions could limit U.S. companies’ ability to access some of the world’s most promising drug candidates. This could shrink U.S. medicine pipelines, put hundreds of billions of dollars in industry value at risk, and ultimately weaken the U.S. biopharmaceutical industry and the R&D ecosystem it supports.